Compare DRDB & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | DRDB | CBIO |
|---|---|---|
| Founded | 2024 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 319.5M | 252.6M |
| IPO Year | 2024 | N/A |
| Metric | DRDB | CBIO |
|---|---|---|
| Price | $10.42 | $13.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $25.60 |
| AVG Volume (30 Days) | 57.5K | ★ 181.7K |
| Earning Date | 01-01-0001 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $595.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.87 | $9.81 |
| 52 Week High | $10.47 | $21.40 |
| Indicator | DRDB | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 48.69 |
| Support Level | $10.43 | $12.27 |
| Resistance Level | $10.47 | $16.35 |
| Average True Range (ATR) | 0.01 | 1.08 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 9.09 | 21.44 |
Roman DBDR Acquisition Corp II is a blank check company.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.